Patients' access to 2018 FDA-approved drugs 1 year post approval.

Objectives: To examine US commercial health plans' adoption of 2018 FDA-approved drugs.

Study Design: Database analysis.

Methods: We identified novel drugs that the FDA approved in 2018 and categorized them as follows: cancer treatment, orphan drug, included in an expedited review program, and biosimilar.

Variation in access to hemophilia A treatments in the United States.

Background: US commercial health plans have been found to vary in how they cover specialty drugs indicated for a range of diseases. In this study, we examined patients' access to hemophilia A (HemA) treatments across a set of large commercial health plans.

Objective: To examine variation in health plans' coverage policies for HemA treatments.

Variation in health plan coverage of ESAs for anemia due to chronic kidney disease.

Because health plans each issue their own policies, drug coverage can vary. This variation can result in patients having unequal access to treatment. In this study, we evaluate commercial health plans' coverage policies for erythropoiesis-stimulating agents (ESAs) for patients with anemia resulting from chronic kidney disease (CKD).

Coverage for Biosimilars vs Reference Products Among US Commercial Health Plans.

This study uses US commercial health plan insurance data to characterize coverage for biosimilar drugs compared with reference products.

What types of real-world evidence studies do U.S. commercial health plans cite in their specialty drug coverage decisions?

Purpose: To examine the RWE U.S. commercial health plans cite in their specialty drug coverage decisions.